DS-2087b
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 20, 2025
Evaluation of interspecies differences in DS-2087b-induced gastrointestinal toxicity using mouse and monkey intestinal organoids.
(PubMed, Toxicol Lett)
- "In the transcriptomic analysis, expression of stem- and Paneth-cell marker genes was markedly decreased in the monkey small intestinal organoids. In conclusion, the intestinal organoids are valuable in vivo-in vitro translation of drug-induced GI toxicity and the changes in specific cell-type composition induced by DS-2087b may be important factors for contributing the interspecies differences."
Journal • Preclinical • Oncology • HER-2
July 21, 2020
[VIRTUAL] Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions
(ESMO 2020)
- "Methods We evaluated the inhibitory effects of DS-2087b and poziotinib, an investigational tyrosine kinase inhibitor against Ba/F3 cells harboring WT EGFR and against EGFR/HER2 ex20ins mutations, including EGFR V769_D770 insertion ASV (EGFR ins.ASV); EGFR D770_N771 insertion SVD (EGFR ins.SVD); and HER2 A775_G776 insertion YVMA (HER2 ins.YVMA). Legal entity responsible for the study: Yuki Abe. Funding: Daiichi Sankyo Company, Limited."
Preclinical • Breast Cancer • HER2 Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR
1 to 2
Of
2
Go to page
1